Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Ionis Pharmaceuticals and partner AstraZeneca announced that the Phase 3 CARDIO-TTRansform trial for eplontersen in ATTR-CM failed to meet its primary endpoint of reducing cardiovascular mortality and recurrent events. The failure is attributed to the high prevalence of stabilizer therapy in the study population, which masked the drug's efficacy in the overall cohort. However, a pre-specified subgroup analysis showed a nominally significant hazard ratio of 0.71 for patients on eplontersen monotherapy.
Key figures
- Drug Name
- eplontersen
- Phase Of Trial
- Phase 3
- Trial enrollment
- 1432
- Hazard ratio monotherapy
- 0.71
- Stabilizer usage baseline
- 57%
- Stabilizer usage during trial
- 24%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.